Tower Cold Chain, a leading specialist in pharmaceutical thermal protection, has reached a significant milestone with the opening of its new headquarters in the Americas region. This 26,000 sq. ft facility, situated in Philadelphia near PHL International Airport, enhances Tower’s capabilities in container conditioning and storage. The establishment of the American Centre of Excellence demonstrates Tower’s commitment to serving pharmaceutical, airline, and 3PL customers across North, Central, and South America.
Replicating Success: Centre of Excellence Model in Philadelphia
Taking inspiration from the success of its Centre of Excellence in the United Kingdom, Tower Cold Chain has replicated this proven model with its latest facility in Philadelphia. The American Centre of Excellence offers state-of-the-art design, laboratory, and testing capabilities to drive the development of temperature-controlled solutions. Moreover, the office space accessible to customers fosters collaboration, enabling meetings, demonstrations, and joint product development.
Collaboration and Innovation: Strengthening Partnerships
With the establishment of the dedicated Centre of Excellence in the Americas, Tower Cold Chain aims to strengthen collaborative partnerships with pharmaceutical manufacturers, airlines, and 3PL providers in the region. This facility will serve as a hub of innovation and expertise, facilitating knowledge exchange and the development of customer-focused solutions. By addressing the evolving challenges in the cold chain logistics industry, Tower Cold Chain endeavors to provide robust and reliable logistics for temperature-sensitive pharmaceutical and life-science products.
Strategic Location: Choosing Philadelphia as the Hub
Tower’s decision to establish the American Centre of Excellence in Philadelphia, Pennsylvania reflects the region’s favorable pharmaceutical business climate, customer proximity, and robust logistics infrastructure.
Favorable Pharmaceutical Business Climate. Philadelphia has emerged as a hub for the pharmaceutical industry, hosting numerous pharmaceutical manufacturers, research institutions, and healthcare organizations. The city’s strong pharmaceutical ecosystem creates a conducive business environment for companies like Tower Cold Chain to thrive. It offers access to a skilled workforce, cutting-edge research facilities, and a supportive regulatory framework. The presence of renowned universities and medical centers further enhances the region’s expertise and fosters innovation in the pharmaceutical field.
Customer Proximity. Proximity to customers is a critical factor in the logistics industry, particularly for time-sensitive and temperature-controlled products like pharmaceuticals. Philadelphia’s central location in the Americas region allows Tower Cold Chain to efficiently serve its pharmaceutical, airline, and 3PL customers across North, Central, and South America. The close proximity to major population centers and key transportation hubs ensures quick and reliable access to markets, facilitating timely and efficient distribution of temperature-sensitive products.
Robust Logistics Infrastructure. Philadelphia boasts a robust logistics infrastructure, including well-connected transportation networks, advanced warehousing facilities, and efficient customs processes. The city is strategically positioned with access to major highways, railways, and seaports, enabling seamless transportation and supply chain operations. Additionally, Philadelphia International Airport, located just 1.6 miles from Tower’s headquarters, offers extensive air cargo capabilities and international connectivity, facilitating global distribution.
Leveraging these advantages, Tower aims to build strong partnerships while supporting its network of hubs throughout the Americas, including locations in Los Angeles, San Francisco, Chicago, and Puerto Rico.
Showcasing Excellence: Open Day Invitation
Tower Cold Chain cordially invites customers, partners, and industry stakeholders to attend the official Open Day on September 12th. This event will provide an opportunity to visit the Centre of Excellence in Philadelphia, witness its cutting-edge facilities, and experience firsthand the expertise and innovation behind Tower’s temperature-controlled solutions. The Open Day promises to be a valuable occasion for networking, knowledge sharing, and exploring future collaborations in the pharmaceutical logistics industry.
In conclusion, the opening of the American Centre of Excellence by Tower Cold Chain represents a significant step in the company’s growth trajectory. By investing in strategic locations and fostering collaborative partnerships, Tower continues to meet the increasing demand for reliable and efficient transportation of temperature-sensitive pharmaceutical and life-science products. The establishment of this facility in Philadelphia showcases Tower’s commitment to excellence and innovation in the cold chain logistics industry.
About Tower Cold Chain
The global pharmaceutical and life science sectors are supplied by Tower Cold Chain with temperature-controlled containers. The company’s mission is to bring customer-focused innovation in temperature- and physically-controlled protection while also adding value to its supply chain.
Tower Cold Chain offers robust, dependable, and reusable (3R) solutions to reliably carry temperature-sensitive goods whenever and wherever required.
Tower Cold Chain is committed to upholding its core principles, which include developing original solutions, providing reliable quality and responsibility for its clients, collaborating as a team, and understanding the significance of taking the environment and sustainability into account in everything it does.
To get in touch with the Americas team, visit:Â https://bit.ly/43ItMhkÂ
Biopharma PEG announces a groundbreaking array of monodispersed PEGs to propel the pharma industry into a new era.
Huateng Pharma has unveiled a suite of advanced anti-diabetes intermediates, featuring compounds intricately designed to target diabetes with unprecedented precision.
Despite advances, key gaps in understanding insulin resistance persist, including CNS diagnostics, brain-periphery interactions, and apoE isoform roles, highlighting critical research priorities for new treatments.
GAS1’s discovery represents a beacon of hope in the fight against metastatic disease.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings